Plasma lamin B1 mRNA showed a much better performance to differentiate between HCC cases and the two control groups, where, at a 2–ΔΔCq cut-off of 1.4, sensitivity was 100%, specificity was 90%, NPV was 100%, PPV was 93.4% and efficacy was 96%, with an AUC =0.962. The gene discussed is LMNB1; the disease is hepatocellular carcinoma.